Clinical outcomes of patients with multiple sclerosis treated with ocrelizumab in a US community MS center: an observational study.

Ocrelizumab effectively controlled relapse risk and disability worsening. Although only 12.1% of patients have discontinued ocrelizumab, infections resulting in hospitalisation are a concern, especially in older and disabled patients.